Pfizer Inc. (PFE): what the price requires
At today's price, Pfizer Inc. (PFE) is priced for -4.3% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-13 · Source: https://boothcheck.com/report/PFE
Headline
| Field | Value |
|---|---|
| Ticker | PFE |
| Company | Pfizer Inc. |
| Current price | $24.50/sh |
| Composition | Biopharma 98% / Pfizer CentreOne 2% / Pfizer Ignite 0% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 6.6% |
| Operating margin today | 20.7% |
| Margin compression implied | -14.1pp |
| Implied growth | -4.3% |
| Multiple paid | 17x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.3pp (computed at the 7% minimum rate; the CAPM rate 6.6% sits below it).
Reconcile: at the x-ray's 9.3% required return this reads ~10.9%/yr; the models below use their own rates.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.29σ |
| cohort percentile (of 112 peers) | 32 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 1.78x | 4 | expensive |
| Earnings | 2.63x | 4 | expensive |
| Relative | 1.10x | 5 | expensive |
| Growth | 0.94x | 5 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.6%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $25.94 | 0.94x | yes | FCF base $9.5B, growth 2% (input: historical growth), terminal g 2.2%, WACC 6.6%, 5yr projection |
| DCF Exit Multiple | Growth | $24.07 | 1.02x | yes | Exit EV/EBITDA: 28.8x / 30.8x / 32.8x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $22.35 | 1.10x | yes | P/E 24x (sector median), scenarios: 20.2x / 24.0x / 27.8x (bear / base = sector held flat / bull), EV/EBITDA 20.45x |
| Simple DDM | Growth | $197.48 | 0.12x | yes | DPS $1.71, g=8.3% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3% |
| Two-Stage DDM | Growth | $60.52 | 0.40x | yes | Stage 1: 20% for 5yr, Stage 2: 3.5% perpetual |
| Simple Excess Return | Asset | $14.13 | 1.73x | yes | BV/sh $15.72, ROE (TTM) 8.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $13.39 | 1.83x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $17.01 | 1.44x | yes | Rev $63.3B, growth 2% (input: historical growth; tapered), Terminal P/S: 1.9x / 2.2x / 2.6x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $15.72 | 1.56x | yes | EPS $1.31, growth 2% (input: historical EPS growth), PEG=9.37 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | $13.27 | 1.85x | yes | BV $15.72 + 5yr PV of (ROE (TTM) 8.3% − Kₑ 9.3%) × BV; BV grows 5.4%/yr |
| Graham Number | Asset | $21.53 | 1.14x | yes | √(22.5 × EPS $1.31 × BVPS $15.72) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $7.44 | 3.29x | yes | EBITDA $6.59B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $6.94 | 3.53x | yes | FCF $9483.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $5.24 | 4.67x | yes | SBC-adj FCF $8.58B (FCF $9.48B − SBC $0.90B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $42.27 | 0.58x | yes | EPS $1.31 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $44.19 | 0.55x | yes | Revenue $63.31B × sector P/S 4.0x |
| PEG Fair Value | Relative | $49.13 | 0.50x | yes | EPS $1.31 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $14.16 | 1.73x | yes | EPS $1.31 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $58.4b |
| Net debt / NOPAT (after-tax) | 5.54x |
| Net debt / operating income (pre-tax) | 4.74x |
| Interest coverage | 4.7x |
| Share count CAGR (buyback) | -0.1% |
| Burning cash | no |
Bullet Takeaways
- Pfizer is essentially one business now, biopharmaceuticals at about 98% of revenue, rebuilt after the COVID windfall faded around a pipeline weighted toward oncology and, more recently, obesity.
- The defining risk is the patent cliff the 10-K spells out, a wave of exclusivity losses "in 2026 through 2030 as several of our in-line products experience these expirations," which the company estimates at roughly $17 billion of revenue impact over 2026 to 2028.
- The number that decides the thesis is dividend coverage: the payout of about $1.72 per share against trailing GAAP earnings near $1.31 means the dividend currently exceeds free cash flow, so the bet is whether the oncology and obesity pipeline lifts cash generation before the patent losses bite.
Bull Case
Look at the earnings trajectory and the bull case becomes a question of inflection rather than decline. Pfizer's revenue settled near $63 billion after the COVID surge unwound, and the company has spent the last two years redeploying that windfall into a pipeline aimed at the two largest growth categories in the industry: oncology and obesity. The $43 billion Seagen acquisition brought a portfolio of antibody-drug conjugates, and the 10-K confirms its scale, noting that "all of the goodwill related to the acquisition of Seagen is related to our Biopharma" segment. The $7 billion Metsera acquisition added next-generation, ultra-long-acting obesity assets, and management plans to start roughly 20 pivotal trials in 2026, including ten for the obesity programs. That is a deliberate reshaping of the earnings base from a COVID-dependent one to a durable oncology-and-obesity one.
The valuation already discounts the decline, which is the bull's strongest structural point. At today's price the methods do not demand growth; the price embeds a slight fade rather than expansion. The growth-DCF methods and the peer-multiple lens land essentially at the price by crediting only the modest cash flow Pfizer reliably generates. For a company trading around a high-single-digit dividend yield with the broadest late-stage pipeline in big pharma, the price is paying for managed decline, not for the pipeline succeeding. If even a portion of the 20 pivotal programs reads out positively, the upside is asymmetric against a price that assumes little.
The balance sheet, while levered, is investment-grade and serviceable. Rating agencies kept Pfizer in the A category through the Metsera financing, and gross leverage near the high-2x range is normal for big pharma carrying acquisition debt. Management is also pulling cost levers, targeting $700 million in manufacturing-optimization savings for the year. The bull case is a beaten-down market leader with a refilled pipeline, a covered-on-adjusted-earnings dividend, and a price that has already written off the patent cliff. The catalyst is data, and there is a great deal of it coming.
Bear Case
The most fragile assumption baked into the price is that the dividend holds, and the cash flow does not currently support it. Pfizer paid roughly $9.8 billion in dividends in 2025 against free cash flow of about $9.1 billion, which means the payout exceeded the cash the business generated. A dividend that consumes more than 100% of free cash flow is funded from the balance sheet, not from operations, and that cannot persist indefinitely. The high yield that draws income investors to the stock is precisely the market signaling doubt about that yield's durability. If the pipeline does not lift cash generation before the patent losses compound, management faces a choice between cutting the dividend and adding leverage, and either outcome breaks the income thesis the price partly rests on.
The patent cliff is the force pressing on all of it. The 10-K is explicit that exclusivity losses arrive "in 2026 through 2030 as several of our in-line products experience these expirations," and once a product loses exclusivity, "generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price." The company itself sizes the revenue impact at roughly $17 billion over 2026 to 2028. That is a quarter of current revenue at risk, and the acquisitions meant to offset it, Seagen and Metsera, are expensive bets whose payoff is years out and probabilistic. Drug pipelines fail far more often than they succeed, and the obesity market Pfizer is buying into is already dominated by entrenched competitors with approved products and head starts measured in years.
The asset-based and earnings-power methods both read expensive at today's price. Capitalizing the company's normalized operating earnings at the cost of capital lands far below the price, because trailing GAAP earnings of $1.31 per share reflect a profit base still depressed by the COVID unwind and acquisition costs. The price requires the pipeline to convert into earnings growth that replaces both the COVID revenue and the patent-cliff losses, on a timeline that beats the exclusivity expirations. Net debt of about $58 billion and interest coverage near five times leave less room to absorb a pipeline disappointment than a fortress balance sheet would. The bear case is not that Pfizer disappears; it is that a price paying for stability is underwriting a transition with binary outcomes and a dividend the cash flow does not yet cover.
Valuation
The price is making a defensive bet: that Pfizer manages its decline rather than reverses it, holding cash flow roughly flat while the pipeline matures. The inversion is undemanding, embedding a slight fade in operating income rather than growth, which tells you the market is not paying for the oncology and obesity bets to succeed. It is paying for the existing business to hold together. For a company facing a $17 billion patent-cliff impact, even a flat-to-slightly-down assumption is not trivially safe, but it is far from the optimism priced into the industry's growth names.
The methods split along the line you would expect for a mature pharma in transition. The peer-multiple lens lands near the price, valuing Pfizer at roughly a sector earnings multiple, and the growth-DCF methods reach it by crediting low-single-digit cash-flow growth. Where the methods say expensive is the static earnings-power and asset lenses: capitalizing free cash flow with no growth, or anchoring on the depressed trailing earnings, both land well below the price. That pattern reflects a business whose current earnings understate its franchise value because the COVID revenue rolled off faster than the new pipeline ramped. The dividend-discount methods, which credit the high payout, technically reach far above the price, but those models assume the dividend grows sustainably, which the free-cash-flow coverage directly contradicts. Reading them at face value would be a mistake the cash-flow reality corrects.
Solvency is where the bet meets its constraint. Net debt of about $58 billion sits on the balance sheet after the Seagen and Metsera acquisitions, with interest coverage near five times, comfortable but not abundant for a company facing a revenue cliff. The dividend, at about $1.72 per share, is the load-bearing concern: it currently exceeds free cash flow, so the downside is not just a multiple compression but a potential dividend cut that would reset the income thesis. The share count has been essentially flat, no buyback offsetting anything. What the buyer is underwriting is a transition: that the late-stage pipeline converts to revenue fast enough to cover both the patent losses and the dividend before the balance sheet has to choose between them.
Catalysts
Pfizer reaffirmed 2026 guidance for revenue of about $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00, with the revenue figure reflecting roughly $5 billion of remaining COVID-product sales and an expected $1.5 billion year-over-year drag from products losing exclusivity. The company frames the larger challenge as roughly $17 billion of patent-cliff revenue impact across 2026 to 2028, which the pipeline and acquisitions are meant to offset. The next quarterly prints are the read on whether the base business holds within guidance as the LOE drag accelerates.
The pipeline is where the upside lives, and 2026 is a heavy data year. Management plans about 20 pivotal trials, including ten for the ultra-long-acting obesity assets acquired in the $7 billion Metsera deal, on top of the oncology portfolio from the $43 billion Seagen acquisition. On costs, the company is targeting $700 million in manufacturing-optimization savings for the year, with a portion already realized. The developments that move the thesis are pivotal-trial readouts, particularly in obesity where Pfizer is a late entrant against established competitors, and any management signal on the dividend, given that the payout currently runs ahead of free cash flow. Those two, pipeline data and dividend posture, are the catalysts that decide whether the transition works.
Peer Cohorts (Per Segment, With Filing Citations)
Biopharma (reported)
- JNJ (Johnson & Johnson)
- (no filing in the citation store)
- BMY (Bristol-Myers Squibb Company)
- (no filing in the citation store)
- AMGN (Amgen Inc.)
- (no filing in the citation store)
- GILD (GILEAD SCIENCES, INC.)
- (no filing in the citation store)
- GSK (GSK plc)
- (no filing in the citation store)
- NVS (Novartis AG)
- (no filing in the citation store)
- LLY (ELI LILLY & Co)
- (no filing in the citation store)
- ABBV (AbbVie Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
company FY2025 results, 2026 · Pfizer FY2026 guidance, 2026 · Pfizer Q1 2026 results, 2026 · Pfizer FY2025 results, 2026